| Identification | Back Directory | [Name]
SJF620 | [CAS]
2376187-16-3 | [Synonyms]
SJF620
SJF-620,SJF620
2,6-Piperidinedione, 3-[5-[2-[2-[2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]ethoxy]ethoxy]ethoxy]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]- | [Molecular Formula]
C41H44N8O7 | [MDL Number]
MFCD32874106 | [MOL File]
2376187-16-3.mol | [Molecular Weight]
760.84 |
| Chemical Properties | Back Directory | [Boiling point ]
988.1±65.0 °C(Predicted) | [density ]
1.44±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
10.73±0.40(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
SJF620 is a PROTAC connected by ligands for Cereblon and Btk with a DC50 of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN[1]. | [in vivo]
SJF620 has a super pharmacokinetic profile in mice (1 mg/kg; i.v.) with the half life (t1/2) of 1.64 h. SJF620 exhibits a significantly better pharmacokinetic profile than MT802[1]. | [IC 50]
Cereblon | [References]
[1] Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 Feb 1;30(3):126877. DOI:10.1016/j.bmcl.2019.126877 |
|
|